DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Expanded Access to Glecaprevir/ Pibrentasvir

Conditions: Hepatitis C Virus Infection

First Posted Date: 2017-04-21

Last Posted Date: 2020-01-18

Lead Sponsor: AbbVie

Registration Number: NCT03123965

Locations: 🇸🇮
Univ Medical Ctr Ljubljana /ID# 161419, Ljubljana, Slovenia

Expanded Access to Venetoclax

Conditions: Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Amyloidosis
Plasma Cell Leukemia

First Posted Date: 2017-04-21

Last Posted Date: 2025-04-04

Lead Sponsor: AbbVie

Registration Number: NCT03123029

Expanded Access to ABT-414

Conditions: Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis

First Posted Date: 2017-04-21

Last Posted Date: 2019-07-15

Lead Sponsor: AbbVie

Registration Number: NCT03123952

Expanded Access to Veliparib

Conditions: Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
Triple Negative Breast Cancer (TNBC)
High Grade Serous Ovarian Cancer
Patients Requiring Veliparib Suspension Formulation

First Posted Date: 2017-04-21

Last Posted Date: 2022-05-24

Lead Sponsor: AbbVie

Registration Number: NCT03123211

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: risankizumab SC
Drug: risankizumab IV
Drug: placebo for risankizumab IV

First Posted Date: 2017-04-07

Last Posted Date: 2022-06-14

Lead Sponsor: AbbVie

Target Recruit Count: 618

Registration Number: NCT03104413

Locations: 🇺🇸
TLC Clinical Research Inc /ID# 212501, Los Angeles, California, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC /ID# 212543, Pittsburgh, Pennsylvania, United States
🇺🇸
Duplicate_Atria Clinical Research /ID# 164504, Little Rock, Arkansas, United States

and more 400 locations

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Phase 3

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Drug: Placebo for Risankizumab SC
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC
Drug: Risankizumab IV
Drug: Risankizumab On-Body Injector (OBI)

First Posted Date: 2017-04-07

Last Posted Date: 2024-12-24

Lead Sponsor: AbbVie

Target Recruit Count: 1336

Registration Number: NCT03105102

Locations: 🇨🇳
Guangdong Provincial People's Hospital /ID# 212949, Guangzhou, Guangdong, China
🇳🇴
Akershus Universitetssykehus /ID# 169379, Nordbyhagen, Akershus, Norway
🇷🇴
Fundeni Clinical Institute /ID# 170899, Bucharest, Romania

and more 493 locations

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Upadacitinib
Drug: Adalimumab
Drug: Placebo to Upadacitinib
Drug: Placebo to Adalimumab

First Posted Date: 2017-04-07

Last Posted Date: 2024-10-01

Lead Sponsor: AbbVie

Target Recruit Count: 1705

Registration Number: NCT03104400

Locations: 🇺🇸
Great Lakes Clinical Trials /ID# 163435, Chicago, Illinois, United States
🇨🇳
1st Aff Hosp of Bengbu Medical College /ID# 201021, Bengbu, Anhui, China
🇨🇳
The First Affiliated Hospital of Shantou University Medical College /ID# 203371, Shantou, Guangdong, China

and more 342 locations

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: ABT-494
Drug: Placebo

First Posted Date: 2017-04-07

Last Posted Date: 2024-11-27

Lead Sponsor: AbbVie

Target Recruit Count: 642

Registration Number: NCT03104374

Locations: 🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC /ID# 160047, Mesa, Arizona, United States
🇺🇸
Sun Valley Arthritis Center Ltd. /ID# 161203, Peoria, Arizona, United States
🇺🇸
Duplicate_AZ Arthritis and Rheumotology Research, PLLC /ID# 160006, Phoenix, Arizona, United States

and more 162 locations

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: risankizumab IV
Drug: risankizumab SC
Drug: placebo for risankizumab

First Posted Date: 2017-04-07

Last Posted Date: 2022-07-06

Lead Sponsor: AbbVie

Target Recruit Count: 931

Registration Number: NCT03105128

Locations: 🇺🇸
The University of Chicago Medical Center /ID# 157141, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC /ID# 210920, Pittsburgh, Pennsylvania, United States
🇨🇳
Renmin Hospital of Wuhan University /ID# 214873, Wuhan, Hubei, China

and more 472 locations

Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab

Completed

Conditions: Psoriasis

First Posted Date: 2017-04-04

Last Posted Date: 2020-03-30

Lead Sponsor: AbbVie

Target Recruit Count: 97

Registration Number: NCT03099083

Locations: 🇰🇷
Hallym University Sacred Heart Hospital /ID# 161697, Anyang-si, Gyeonggi-do, Gyeonggido, Korea, Republic of
🇰🇷
CHA Bundang Medical center, CHA University /ID# 161696, Seongnam-si, Gyeonggido, Korea, Republic of
🇰🇷
Ajou University Hospital /ID# 161698, Suwon-si, Gyeonggido, Korea, Republic of

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy